# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...
RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $175 price target.
Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated di...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will...
Johnson & Johnson (NYSE:JNJ) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc., ...
Johnson & Johnson's Megadyne Mega Soft Pediatric Patient Return Electrodes recalled due to patient burns. FDA's Cla...
Kenvue Inc. (NYSE:KVUE) ("Kenvue") announced today the launch of a secondary underwritten public offering (the "Off...